Short answer
Bristol Myers Squibb (BMY) filed its Q1 2025 10-Q quarterly report on Apr 24, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $11.2B (down 5.6% year over year) with net income of $2.5B.
Q1 2025 key financials · XBRL
- Revenue
- $11.2B
- −5.6% YoY
- Net income
- $2.5B
- +120.6% YoY
- EPS (diluted)
- $1.20
- +120.4% YoY
Source: XBRL data from the Bristol Myers Squibb (BMY) Q1 2025 10-Q on SEC EDGAR. USD.
Bristol Myers Squibb Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or materially updated risk factors disclosed in the section, risk profile consistent with 10-K
- Regulatory risk from reliance on FDA and EC approvals for key products like Opdivo + Yervoy expansions in HCC and CRC in 2025
- Operational risk from ongoing integration of recent approvals including Camzyos in Japan and Breyanzi in EU impacting near-term launch efforts
- Competitive risk due to rapidly evolving immuno-oncology market with multiple first-line approvals overlapping Bristol Myers Squibb’s indications
- No financial risks such as liquidity or debt maturity changes mentioned in this section
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bristol Myers Squibb quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.